B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target

B. Riley Securities initiated coverage on Precigen's stock with a rating of Buy and a price target of $12.00.The price target implies an upside of 55.8% from the Sep 24 close of $7.70.Key takeaways from the analyst noteStrong Clinical Pipeline: Precigen's clinical pipeline features innovative thera…